Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2019

01-10-2019 | Breast Cancer | Review

Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression

Authors: Winnie Yeo, Takayuki Ueno, Ching-Hung Lin, Qiang Liu, Kyung-Hun Lee, Roland Leung, Yoichi Naito, Yeon Hee Park, Seock-Ah Im, Huiping Li, Yoon Sim Yap, Yen-Shen Lu, The Asian Breast Cancer Cooperative Group

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Login to get access

Abstract

Purpose

Breast cancer in young Asian women has distinctive clinicopathological characteristics; hence, we question the universal generalizability of treatment recommendations based on data from predominantly non-Asian postmenopausal women.

Methods

The Asian Breast Cancer Cooperative Group (ABCCG) reviewed current ESO-ESMO and St. Gallen recommendations for treating hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) breast cancer in premenopausal women. Points disputed by ≥ 3/12 members were discussed, and statements on contentious issues formulated for anonymous voting; consensus required a ≥ 75% majority.

Results

The ABCCG contends that: (1) Trials in premenopausal women are not only necessary, but also worthwhile if performed separately from others that also enroll postmenopausal participants. (2) Not all premenopausal women with HR+ early breast cancer need adjuvant ovarian function suppression (OFS). (3) Certain clinical factors might influence decision-making about prescribing OFS. (4) For early HR+/HER2− breast cancer in premenopausal patients with OFS, tamoxifen is preferred for intermediate-risk cases; for high risk, near-consensus supported aromatase inhibitor, despite no clear overall survival benefit versus tamoxifen. (5) Oncotype DX Breast Recurrence Score® has different treatment implications in patients aged ≤ 50 versus > 50 years. (6) High-risk patients (if premenopausal after chemotherapy) should receive adjuvant chemotherapy and OFS plus aromatase inhibitor. (7) For patients with advanced disease receiving OFS on a backbone of tamoxifen, gonadotrophin-releasing hormone agonists may be given 12-weekly. (8) For premenopausal women who decline OFS or oophorectomy, tamoxifen alone is still an option but is considered less effective; other monotherapies are also less effective than OFS plus such treatments.

Conclusion

Premenopausal Asian women with breast cancer have unique disease characteristics and may benefit from treatment that differs somewhat from international guidelines. Given the great diversity of patients and clinical settings worldwide, the ABCCG advocates evidence-based yet flexible and individualized use of all potential options to improve breast cancer outcomes.
Appendix
Available only for authorised users
Footnotes
1
This consensus statement largely represents evidence from East Asian countries/regions, including China, Hong Kong, Japan, Singapore, Taiwan, and South Korea, for which robust epidemiologic data and expert knowledge of ABCCG members are available.
 
Literature
1.
Porter P (2008) “Westernizing” women’s risks? Breast cancer in lower-income countries. N Engl J Med 358:213–216CrossRefPubMed
2.
Shin HR, Joubert C, Boniol M, Hery C, Ahn SH, Won YJ, Nishino Y, Sobue T, Chen CJ, You SL, Mirasol-Lumague MR, Law SC, Mang O, Xiang YB, Chia KS, Rattanamongkolgul S, Chen JG, Curado MP, Autier P (2010) Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control 21:1777–1785CrossRefPubMed
3.
Youlden DR, Cramb SM, Yip CH, Baade PD (2014) Incidence and mortality of female breast cancer in the Asia-Pacific region. Cancer Biol Med 11:101–115PubMedPubMedCentral
4.
Kim Y, Yoo KY, Goodman MT (2015) Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. Asian Pac J Cancer Prev 16:2857–2870CrossRefPubMed
5.
Huang Z, Wen W, Zheng Y, Gao YT, Wu C, Bao P, Wang C, Gu K, Peng P, Gong Y, Zhang M, Xiang Y, Zhong W, Jin F, Xiang YB, Shu XO, Beeghly-Fadiel A (2016) Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, China. Ann Oncol 27:1129–1134CrossRefPubMedPubMedCentral
6.
Cheng Y, Yan Y, Gong J, Yang N, Nie S (2018) Trends in incidence and mortality of female breast cancer during transition in Central China. Cancer Manag Res 10:6247–6255CrossRefPubMedPubMedCentral
7.
Shen YC, Chang CJ, Hsu C, Cheng CC, Chiu CF, Cheng AL (2005) Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomark Prev 14:1986–1990CrossRef
8.
9.
Song QK, Li J, Huang R, Fan JH, Zheng RS, Zhang BN, Zhang B, Tang ZH, Xie XM, Yang HJ, He JJ, Li H, Li JY, Qiao YL, Chen WQ (2014) Age of diagnosis of breast cancer in China: almost 10 years earlier than in the United States and the European Union. Asian Pac J Cancer Prev 15:10021–10025CrossRefPubMed
10.
Lin CH, Chuang PY, Chiang CJ, Lu YS, Cheng AL, Kuo WH, Huang CS, Lai MS, You SL, Tang CH (2014) Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cacer registry-based study. Oncologist 19:583–591CrossRefPubMedPubMedCentral
11.
Huang CS, Lin CH, Lu YS, Shen CY (2010) Unique features of breast cancer in Asian women–breast cancer in Taiwan as an example. J Steroid Biochem Mol Biol 118:300–303CrossRefPubMed
12.
13.
Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL (2009) Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomark Prev 18:1807–1814CrossRef
14.
Kurebayashi J, Miyoshi Y, Ishikawa T, Saji S, Sugie T, Suzuki T, Takahashi S, Nozaki M, Yamashita H, Tokuda Y, Nakamura S (2015) Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011. Breast Cancer 22:235–244CrossRefPubMed
15.
Lin CH, Chen YC, Chiang CJ, Lu YS, Kuo KT, Huang CS, Cheng WF, Lai MS, You SL, Cheng AL (2012) The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer 130:2629–2637CrossRefPubMed
16.
17.
Yap YS, Singh AP, Lim JHC, Ahn JH, Jung KH, Kim J, Dent RA, Ng RCH, Kim SB, Chiang DY (2018) Elucidating therapeutic molecular targets in premenopausal Asian women with recurrent breast cancers. NPJ Breast Cancer 4:19CrossRefPubMedPubMedCentral
18.
Kan Z, Ding Y, Kim J, Jung HH, Chung W, Lal S, Cho S, Fernandez-Banet J, Lee SK, Kim SW, Lee JE, Choi YL, Deng S, Kim JY, Ahn JS, Sha Y, Mu XJ, Nam JY, Im YH, Lee S, Park WY, Nam SJ, Park YH (2018) Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures. Nat Commun 9:1725CrossRefPubMedPubMedCentral
19.
Michaud LB, Jones KL, Buzdar AU (2001) Combination endocrine therapy in the management of breast cancer. Oncologist 6:538–546CrossRefPubMed
20.
Cortés J, Im SA, Holgado E, Perez-Garcia JM, Schmid P, Chavez-MacGregor M (2017) The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: triplet combination-based endocrine therapies. Cancer Treat Rev 61:53–60CrossRefPubMed
21.
Im SA, Sohn J, Tripathy D, Chow L, Lee KS, Jung KH, Babu G, Im YH, El Saghir N, Liu MC, Diaz-Padilla I, Alam J, Kong O, Miller M, Lu YS (2018) Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): results from the randomized phase III MONALEESA-7 study. Ann Oncol 29(Suppl 9):ix13–ix20. https://​doi.​org/​10.​1093/​annonc/​mdy428 CrossRef
22.
23.
Lertkhachonsuk AA, Yip CH, Khuhaprema T, Chen DS, Plummer M, Jee SH, Toi M, Wilailak S, Summit Asian Oncology (2013) (2103) Cancer prevention in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013. Lancet Oncol 14:e497–507CrossRefPubMed
24.
Bardia A, Hurvitz S (2018) Targeted therapy for premenopausal women with HR+ , HER2- advanced breast cancer: focus on special considerations and latest advances. Clin Cancer Res 24:5206–5218CrossRefPubMed
25.
26.
Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, Lynch J, Friedlander M, Lee CK (2019) The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis. Breast Cancer Res Treat 174:271–278CrossRefPubMed
27.
Cardoso F, Senkus E, Costa A et al (2018) 4th ESO-ESMO International consensus guidelines for advanced Breast Cancer (ABC 4). Ann Oncol 29:1634–1657CrossRefPubMed
28.
Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017 (2017) De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol 28:1700–1712CrossRefPubMedPubMedCentral
29.
Francis PA, Pagani O, Fleming GF, SOFT and TEXT Investigators and the International Breast Cancer Study Group et al (2018) Tailoring adjuvant endocrine therapy for premenopausal Breast Cancer. N Engl J Med 379:122–137CrossRefPubMedPubMedCentral
30.
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465–2472CrossRefPubMed
31.
Hortobagyi GN, Stemmer SM, Burris HA et al (2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738–1748CrossRefPubMed
32.
Tripathy D, Im SA, Colleoni M et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19:904–915CrossRefPubMed
33.
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ (2016) Palbociclib and letrozole in advanced Breast cancer. N Engl J Med 375:1925–1936CrossRefPubMed
34.
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425–439CrossRefPubMed
35.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A (2017) MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35:2875–2884CrossRefPubMed
36.
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A (2017) MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35:3638–3646CrossRefPubMed
37.
André F, Ciruelos EM, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D (2018) Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): results of the phase III SOLAR-1 trial. Ann Oncol 29(Suppl 8):Abstract LBA3_PR. https://​doi.​org/​10.​1093/​annonc/​mdy424.​010 CrossRef
38.
Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377:523–533CrossRefPubMed
39.
Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roché H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379:753–763CrossRefPubMed
40.
Baselga J, Dent SF, Cortés J, Im YH, Diéras V, Harbeck N et al (2018) Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER. J Clin Oncol 36(18_suppl):Abstract LBA1006CrossRef
41.
United States National Cancer Institute S, Epidemiology, and End Results (SEER) Program. (www.​seer.​cancer.​gov) SEER*Stat Database: Incidence –SEER 9 Regs Research Data, Nov 2015 Sub (1973-2013) < Katrina/Rita Population Adjustment > –Linked To County Attributes –Total U.S., 1969–2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission
42.
Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W; Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists’ Group (2003) Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711–1717CrossRef
43.
Bedard PL, Di Leo A, Piccart-Gebhart MJ (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7:22–36CrossRefPubMed
44.
Baum M, Hackshaw A, Houghton J, Rutqvist, Fornander T, Nordenskjold B, Nicolucci A, Sainsbury R; ZIPP International Collaborators Group (2006) Adjuvant goserelin in pre-menopausal patients with early breast cancer: results from the ZIPP study. Eur J Cancer 42:895–904CrossRef
45.
Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ (2014) Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 32:3948–3958CrossRefPubMedPubMedCentral
46.
Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, Balic M, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelda P, Ploner F, Bartsch R, Fesl C, Greil R, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria (2015) Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Ann Oncol 26:313–320CrossRefPubMed
47.
Regan MM, Pagani O, Francis PA, Fleming GF, Walley BA, Kammler R, Dell’Orto P, Russo L, Szőke J, Doimi F, Villani L, Pizzolitto S, Öhlschlegel C, Sessa F, Peg Cámara V, Rodríguez Peralto JL, MacGrogan G, Colleoni M, Goldhirsch A, Price KN, Coates AS, Gelber RD, Viale G; SOFT and TEXT Investigators and International Breast Cancer Study Group (2015) Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Breast Cancer Res Treat 154:275–286CrossRef
48.
Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, Gómez HL, Burstein HJ, Parmar V, Torres R, Stewart J, Bellet M, Perelló A, Dane F, Moreira A, Vorobiof D, Nottage M, Price KN, Coates AS, Goldhirsch A, Gelber RD, Colleoni M, Fleming GF; SOFT; TEXT Investigators; International Breast Cancer Study Group (2017) Treatment efficacy, adherence, and quality of Life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol 35:3113–3122CrossRef
49.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in Breast cancer. N Engl J Med 379:111–121CrossRefPubMedPubMedCentral
50.
Liem GS, Mo FK, Pang E, Suen JJ, Tang NL, Lee KM, Yip CH, Tam WH, Ng R, Koh J, Yip CC, Kong GW, Yeo W (2015) Chemotherapy-related amenorrhea and menopause in young Chinese Breast cancer patients: analysis on incidence, risk factors and serum hormone profiles. PLoS ONE 10:e0140842CrossRefPubMedPubMedCentral
51.
National Comprehensive Cancer Network. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.1.2019. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed 16 April 2019. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way
52.
Rossi E, Morabito A, Rella De, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De Maio E, Di Maio M, Piccirillo MC, De Feo G, D’Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, de Matteis A (2009) Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 27:3192–3197CrossRefPubMed
53.
Lutchman SK, Davies M, Chatterjee R (2005) Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 11:69–89CrossRef
54.
Noguchi S, Kim HJ, Jesena A, Parmar V, Sato N, Wang HC, Lokejaroenlarb S, Isidro J, Kim KS, Itoh Y, Shin E (2016) Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer. Breast Cancer 23:771–779CrossRefPubMed
55.
Masuda N, Iwata H, Rai Y, Anan K, Takeuchi T, Kohno N, Takei H, Yanagita Y, Noguchi S (2011) Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat 126:443–451CrossRefPubMed
56.
Young OE, Renshaw L, Macaskill EJ, White S, Faratian D, Thomas JS, Dixon JM (2008) Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer. Eur J Cancer 44:391–399CrossRefPubMed
57.
58.
Ambros T, Zeichner SB, Zaravinos J, Montero AJ, Ahn E, Aruna M, Kronish L, Mahtani RL, Vogel CL (2014) A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat 146:7–14CrossRefPubMed
59.
Martín M, Kahan Z, Carrasco E, Bartlett CH, Casas M, Gig-Gil M, Muñoz M, Ciruelos EM, Ruiz-Borrego M, Margelí M, Antón A, Bermejo B, Morales S, Gal-Yam E, Koehler M, García-Sáenz JA, de la Haba J, Chacón I, Zielinski C (2017) Abstract OT2-01-06: phase III study of palbociclib (PD-0332991) in combination with endocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to aromatase inhibitors. “The PEARL study” (GEICAM/2013-02). Cancer Res 77(4 suppl):Abstract OT2-01-06. https://​doi.​org/​10.​1158/​1538-7445.​SABCS16-OT2-01-06 CrossRef
60.
Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol 25:2357–2362CrossRefPubMedPubMedCentral
61.
Royce M, Bachelot T, Villanueva C, Özgüroglu M, Azevedo SJ, Cruz FM, Debled M, Hegg R, Toyama T, Falkson C, Jeong J, Srimuninnimit V, Gradishar WJ, Arce C, Ridolfi A, Lin C, Cardoso F (2018) Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced Breast cancer: a clinical trial. JAMA Oncol 4:977–984CrossRefPubMedPubMedCentral
62.
Robson ME, Tung N, Conte P, Im SA, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek SM (2019) OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. https://​doi.​org/​10.​1093/​annonc/​mdz012 CrossRefPubMedPubMedCentral
63.
Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J (2018) Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: overall survival results from BELLE-2. Eur J Cancer 103:147–154CrossRefPubMed
64.
Metadata
Title
Treating HR+/HER2− breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
Authors
Winnie Yeo
Takayuki Ueno
Ching-Hung Lin
Qiang Liu
Kyung-Hun Lee
Roland Leung
Yoichi Naito
Yeon Hee Park
Seock-Ah Im
Huiping Li
Yoon Sim Yap
Yen-Shen Lu
The Asian Breast Cancer Cooperative Group
Publication date
01-10-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05318-5

Other articles of this Issue 3/2019

Breast Cancer Research and Treatment 3/2019 Go to the issue

Epidemiology

Quantifying the relationship between age at diagnosis and breast cancer-specific mortality

Preclinical study

β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer

Preclinical study

Infiltration by myeloperoxidase-positive neutrophils is an independent prognostic factor in breast cancer

Preclinical study

Non-contrast MRI for breast screening: preliminary study on detectability of benign and malignant lesions in women with dense breasts

Clinical trial

The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer

Epidemiology

Mode of detection and breast cancer mortality by follow-up time and tumor characteristics among screened women in Cancer Prevention Study-II
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits